Cargando…
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606547/ https://www.ncbi.nlm.nih.gov/pubmed/34820398 http://dx.doi.org/10.3389/fmed.2021.763773 |
_version_ | 1784602355628507136 |
---|---|
author | Brauneck, Franziska Weimer, Pauline Schulze zur Wiesch, Julian Weisel, Katja Leypoldt, Lisa Vohwinkel, Gabi Fritzsche, Britta Bokemeyer, Carsten Wellbrock, Jasmin Fiedler, Walter |
author_facet | Brauneck, Franziska Weimer, Pauline Schulze zur Wiesch, Julian Weisel, Katja Leypoldt, Lisa Vohwinkel, Gabi Fritzsche, Britta Bokemeyer, Carsten Wellbrock, Jasmin Fiedler, Walter |
author_sort | Brauneck, Franziska |
collection | PubMed |
description | Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD). Methods: The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML (n = 10) and MM (n = 11) were assessed in comparison to corresponding CD4(+) and CD8(+) T cells and peripheral blood- (PB) derived γδ T cells from HDs (n = 16) using multiparameter flow cytometry. Results: BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27(−)CD45RA(++) cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4(+) T cell population, with expression levels that were similar to that on CD8(+) effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1(+)-, TIGIT(+)-, TIM-3(+), and CD39(+) cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT. Conclusion: Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential. |
format | Online Article Text |
id | pubmed-8606547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86065472021-11-23 Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma Brauneck, Franziska Weimer, Pauline Schulze zur Wiesch, Julian Weisel, Katja Leypoldt, Lisa Vohwinkel, Gabi Fritzsche, Britta Bokemeyer, Carsten Wellbrock, Jasmin Fiedler, Walter Front Med (Lausanne) Medicine Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they represent attractive effectors for immuno-therapeutic strategies with a better safety profile and a more favorable anti-tumor efficacy in comparison to conventional αβ T cells. Also, remarkable progress has been achieved re-activating exhausted T lymphocytes with inhibitors of co-regulatory receptors e.g., programmed cell death protein 1 (PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT) and of the adenosine pathway (CD39, CD73). Regarding γδ T cells, little evidence is available. This study aimed to immunophenotypically characterize γδ T cells from patients with diagnosed acute myeloid leukemia (AML) in comparison to patients with multiple myeloma (MM) and healthy donors (HD). Methods: The frequency, differentiation, activation, and exhaustion status of bone marrow- (BM) derived γδ T cells from patients with AML (n = 10) and MM (n = 11) were assessed in comparison to corresponding CD4(+) and CD8(+) T cells and peripheral blood- (PB) derived γδ T cells from HDs (n = 16) using multiparameter flow cytometry. Results: BM-infiltrating Vδ1 T cells showed an increased terminally differentiated cell population (TEMRAs) in AML and MM in comparison to HDs with an aberrant subpopulation of CD27(−)CD45RA(++) cells. TIGIT, PD-1, TIM-3, and CD39 were more frequently expressed by γδ T cells in comparison to the corresponding CD4(+) T cell population, with expression levels that were similar to that on CD8(+) effector cells in both hematologic malignancies. In comparison to Vδ2 T cells, the increased frequency of PD-1(+)-, TIGIT(+)-, TIM-3(+), and CD39(+) cells was specifically observed on Vδ1 T cells and related to the TEMRA Vδ1 population with a significant co-expression of PD-1 and TIM-3 together with TIGIT. Conclusion: Our results revealed that BM-resident γδ T cells in AML and MM express TIGIT, PD-1, TIM-3 and CD39. As effector population for autologous and allogeneic strategies, inhibition of co-inhibitory receptors on especially Vδ1 γδ T cells may lead to re-invigoration that could further increase their cytotoxic potential. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606547/ /pubmed/34820398 http://dx.doi.org/10.3389/fmed.2021.763773 Text en Copyright © 2021 Brauneck, Weimer, Schulze zur Wiesch, Weisel, Leypoldt, Vohwinkel, Fritzsche, Bokemeyer, Wellbrock and Fiedler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Brauneck, Franziska Weimer, Pauline Schulze zur Wiesch, Julian Weisel, Katja Leypoldt, Lisa Vohwinkel, Gabi Fritzsche, Britta Bokemeyer, Carsten Wellbrock, Jasmin Fiedler, Walter Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title | Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title_full | Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title_fullStr | Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title_full_unstemmed | Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title_short | Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma |
title_sort | bone marrow-resident vδ1 t cells co-express tigit with pd-1, tim-3 or cd39 in aml and myeloma |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606547/ https://www.ncbi.nlm.nih.gov/pubmed/34820398 http://dx.doi.org/10.3389/fmed.2021.763773 |
work_keys_str_mv | AT brauneckfranziska bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT weimerpauline bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT schulzezurwieschjulian bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT weiselkatja bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT leypoldtlisa bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT vohwinkelgabi bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT fritzschebritta bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT bokemeyercarsten bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT wellbrockjasmin bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma AT fiedlerwalter bonemarrowresidentvd1tcellscoexpresstigitwithpd1tim3orcd39inamlandmyeloma |